Johnson & Johnson (JNJ.US) halts Phase 2 study of bladder cancer therapy TAR-200

Johnson & Johnson (JNJ.US) said it has halted its Phase 2 study of TAR-200, a therapy for patients with muscle-invasive bladder cancer (MIBC), due to disappointing data. The study, known as SunRISe-2, was stopped after a mid-study analysis showed the treatment was not superior to standard-of-care chemotherapy, according to reports. However, the company said in a statement that it still plans to file for approval of TAR-200 as a single agent for non-muscle-invasive bladder cancer (NMIBC) in early 2025. The company added: "We remain confident in the sales potential of the TARIS platform of over $5 billion."